Sensus Healthcare, Inc. - Common Stock (SRTS)

3.2200
+0.00 (0.00%)
NASDAQ · Last Trade: Nov 13th, 9:05 AM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close3.220
Open-
Bid2.760
Ask3.600
Day's RangeN/A - N/A
52 Week Range2.660 - 5.490
Volume30
Market Cap53.01M
PE Ratio (TTM)-3.426
EPS (TTM)-0.9
Dividend & YieldN/A (N/A)
1 Month Average Volume490,132

Chart

About Sensus Healthcare, Inc. - Common Stock (SRTS)

Sensus Healthcare Inc is a medical technology company that specializes in developing innovative solutions for the treatment of non-melanoma skin cancers and other dermatological conditions. The company focuses on providing non-invasive and effective therapies, particularly through its proprietary Sensus device that utilizes ultrasound technology for the precise targeting of cancerous tissues. In addition to skin cancer treatment, Sensus Healthcare also explores applications in other areas of oncology and dermatology, aiming to improve patient outcomes while minimizing side effects associated with traditional treatment methods. The company's commitment to research and development allows it to drive advancements in medical care, enhancing the quality of life for patients. Read More

News & Press Releases

Sensus Healthcare (SRTS) Q3 2026 Earnings Call Transcriptfool.com
Three systems on rental or Fair Deal terms shifted how revenue was recognized.
Via The Motley Fool · November 13, 2026
What Sensus Healthcare (SRTS) Said on Its Q3 Earnings Callmarketbeat.com
Sensus Healthcare (NASDAQ:SRTS) reported lower third-quarter revenue despite shipping more superficial radiation therapy systems, as product mix and the absence of sales to its historically largest customer weighed on the top line. Revenue fell 13% to $6 million from $6.9 million a year earlier, wh
Via MarketBeat · November 12, 2026
Sensus Healthcare Reports Third Quarter 2026 Financial Results and Business Highlights
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended September 30, 2026.
By Sensus Healthcare, Inc. · Via Business Wire · November 12, 2026
Sensus Healthcare Announces Sale of 1,000th SRT System, Marking Significant Commercial Milestone
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the sale of its 1,000th superficial radiotherapy (SRT) system, representing an important achievement in the Company's commercial development.
By Sensus Healthcare, Inc. · Via Business Wire · November 10, 2026
Sensus Healthcare Inc (NASDAQ:SRTS) Misses Q1 Estimates as Revenue Drops, But New CPT Codes Provide a Tailwindchartmill.com
Via Chartmill · May 7, 2026
Sensus Healthcare Inc (NASDAQ:SRTS) Stock Plummets After Q4 Earnings and Revenue Misschartmill.com
Via Chartmill · February 12, 2026
Unusual Volume Movers: US Stocks on Nov. 4, 2026chartmill.com
Via Chartmill · November 4, 2026
Sensus Healthcare to Report Third Quarter 2026 Financial Results and Hold Business Update Conference Call on November 12, 2026
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the third quarter of 2026 on Thursday, November 12, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.
By Sensus Healthcare, Inc. · Via Business Wire · October 29, 2026
Sensus (SRTS) Q2 2026 Earnings Call Transcriptfool.com
Financing delays crushed Q2 revenue, but management expects recovery in Q3.
Via The Motley Fool · August 20, 2026
Sensus Healthcare Q2 Earnings Call Highlightsmarketbeat.com
Sensus Healthcare (NASDAQ:SRTS) reported second-quarter revenue of $2.3 million, down from $7.3 million a year earlier, as delayed third-party financing prevented the company from recognizing revenue tied to eight equipment units before the end of June. Chairman and Chief Executive Officer Joe Sard
Via MarketBeat · August 13, 2026
Full Transcript: Sensus Healthcare Q2 2026 Earnings Callbenzinga.com
Sensus Healthcare (NASDAQ:SRTS) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive
Via Benzinga · August 13, 2026
Sensus Healthcare Reports Second Quarter 2026 Financial Results and Business Highlights
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026.
By Sensus Healthcare, Inc. · Via Business Wire · August 13, 2026
Sensus Healthcare to Report Second Quarter 2026 Financial Results and Hold Business Update Conference Call on August 13, 2026
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the second quarter of 2026 on Thursday, August 13, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.
By Sensus Healthcare, Inc. · Via Business Wire · July 30, 2026
Sensus Healthcare Q1 Earnings Call Highlightsmarketbeat.com
Sensus Healthcare (NASDAQ:SRTS) said its first quarter of 2026 marked a transition period as new dedicated CPT codes for superficial radiotherapy took effect, while revenue declined from the prior year due largely to the absence of sales to its historically largest customer. Chairman and Chief Exec
Via MarketBeat · May 8, 2026
Sensus (SRTS) Q1 2026 Earnings Transcriptfool.com
Sensus (SRTS) Q1 2026 Earnings Transcript
Via The Motley Fool · May 7, 2026
Sensus Healthcare Reports First Quarter 2026 Financial Results and Business Highlights
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended March 31, 2026.
By Sensus Healthcare, Inc. · Via Business Wire · May 7, 2026
Sensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the first quarter of 2026 on Thursday, May 7, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.
By Sensus Healthcare, Inc. · Via Business Wire · April 23, 2026
Sensus Healthcare Files Lawsuit Against SkinCure Oncology for Breach of Contract
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the filing of a lawsuit in the Circuit Court for the Fifteenth Judicial Circuit in and for Palm Beach County, Florida, against SkinCure Oncology, LLC (SkinCure) alleging breach of contract related to unpaid amounts owed for Sensus products that have been delivered, accepted and deployed into clinical use.
By Sensus Healthcare, Inc. · Via Business Wire · March 27, 2026
Sensus Healthcare Introduces Sensus Link, Brings Advanced Operating Capabilities to the SRT-100™ Installed Base
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, introduces Sensus Link, a cloud-based software and connectivity solution intended to expand advanced operating capabilities across the Company’s SRT-100™ system installed base.
By Sensus Healthcare, Inc. · Via Business Wire · February 26, 2026
Sensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the launch of Sensus Healthcare Financial Services, a new program intended to make it easier for dermatology practices to acquire Sensus’ superficial radiotherapy (SRT) systems through a streamlined process and flexible financing structures.
By Sensus Healthcare, Inc. · Via Business Wire · February 18, 2026
Sensus Healthcare SRTS Q4 2025 Earnings Transcriptfool.com
Sensus Healthcare SRTS Q4 2025 Earnings Transcript
Via The Motley Fool · February 12, 2026
Sensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and twelve months ended December 31, 2025.
By Sensus Healthcare, Inc. · Via Business Wire · February 12, 2026
Sensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the company will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Management will hold a conference call beginning at 4:30 p.m. Eastern time to review the results, provide a business update and answer questions.
By Sensus Healthcare, Inc. · Via Business Wire · February 5, 2026
Sensus Healthcare to Hold Investor Meetings During JPM Week 2026 in San Francisco
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced that management will be meeting with members of the healthcare investment community January 12–14, 2026, in San Francisco during the 44th Annual J.P. Morgan Healthcare Conference.
By Sensus Healthcare, Inc. · Via Business Wire · January 7, 2026
Sensus Healthcare Appoints Larry Biscotti to its Board of Directors
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors.
By Sensus Healthcare, Inc. · Via Business Wire · January 7, 2026